A new U.S. study from Johnson & Johnson (NYSE: JNJ) reveals that most people living with psoriasis — and their healthcare providers — strongly prefer effective ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Picankibart is a recombinant anti-interleukin 23p19 ...
If topical medications haven’t been strong enough to control your psoriasis, your dermatologist may recommend a biologic, a type of drug that targets the part of the immune system responsible for ...
The webinar will be broadcast via Zoom. Interested participants can register using the following LINK. The discussion will provide an in-depth exploration of the plaque psoriasis landscape, current ...
In the VALOR trial, brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared ...
NEW YORK (Reuters Health) - Injections of a protein called interleukin-4 (IL-4) seem equal to the best therapy now available for relieving symptoms of the chronic skin condition psoriasis, the results ...
Oruka Therapeutics, Inc. (($ORKA)) announced an update on their ongoing clinical study. Oruka Therapeutics, Inc. is conducting a study titled ‘A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback